| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2006-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b83b5929fadb30ada61df1f7fdf72324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67b033bbd6ed099a31533f6ae8036a00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_030b7a6c0c0b5a95b3172dabb67477dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13f2e75de7b98429bae3b68f3b572d7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c651ad489b4e5182b1d3a7b843411ff7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdfdc3f3ed07d1c7829722f55981459e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9f9a62a100d1f533b6a56b0b9023e70 |
| publicationDate |
2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1848406-B1 |
| titleOfInvention |
Peroral solid dosage form for contraception comprising dienogest and ethinylestradiol |
| abstract |
Disclosed is a solid peroral contraceptive drug containing 17a-cyanomethyI-17-ß-hydroxyestra-4,9-dien-3on (dienogest) at a daily dose that is equal to or smaller than 2.0 mg as one active component and 17a-ethinyl estradiol (ethinyl estradiol) at a daily dose of less than 0.03 mg as another active component along with one or several pharmaceutically acceptable carriers. The dienogest is proportionately released in at least two phases while the ethinyl estradiol is released at the same time as the first phase of the dienogest. |
| priorityDate |
2005-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |